Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senna laxative further Ames testing would not resolve safety -- FDA.

This article was originally published in The Tan Sheet

Executive Summary

SENNA AMES MUTAGENICITY NEW TESTING NOT NECESSARY, FDA says in a letter to Purdue Frederick recently made available by the agency. FDA still intends to reclassify several stimulant laxative ingredients, including senna, from Category I (safe and effective) to Category III (more data needed). However, the agency points out, "there are sufficient Ames test data in the literature showing that the senna extracts emodin, chrysophanol and aloe-emodin are positively genotoxic, while sennosides A and B are negative," the letter states. "Therefore, no new Ames testing for senna is necessary."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel